Clinical trials
catalyst calendar across sponsors →Studies where MLYS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 with posted results
Held by 14 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, D. E. Shaw & Co., Inc., +9 more) · FINRA short interest 15.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 8 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430Change from MLS-101-301 baseline automated office blood pressureNon-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: lorundrostat, Placebo | Hypertension | 1,076 | 2025-12-30actual | 2026-07-24 |
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454Placebo-adjusted Change From Baseline in AHI at Week 4Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Lorundrostat, Placebo | Obstructive Sleep Apnea, Hypertension | 48 | 2025-12-17actual | 2026-01-13 |
| Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaNCT06150924results2026-06-03Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD | Chronic Kidney Disease | 60 | 2025-02-27actual | 2026-06-03 |
| A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenNCT05769608Change in 24-hour average ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Hypertension | 285 | 2025-01-15actual | 2026-01-20 |
| Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placeboRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Hypertension | 1,083 | 2024-12-10actual | 2026-05-01 |
| Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled HypertensionNCT05001945results2024-01-05Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MLS-101 (Part I), MLS-101 (Part II) · Other: Placebo (Part I), Placebo (Part II) | Hypertension, Renal | 200 | 2022-09-07actual | 2024-01-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19